Continuing Access to In-Home IVIG Act
Do you support it?
Want to know if it passes?
We'll email you when HR 7839 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on HR 7839.
You're tracking HR 7839
We'll email you the moment it moves.
HR 7839 — Continuing Access to In-Home IVIG Act
Last action — Referred to the Subcommittee on Health.
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
✓In Committee
-
Died in session
This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Summary
Extends the Medicare Intravenous Immune Globulin (IVIG) Demonstration for an additional two years and expands the maximum number of participating beneficiaries from 4,000 to 6,500. The program provides bundled payments for items and services that are necessary for in-home IVIG administration for certain beneficiaries with primary immune deficiency disease.
Bill Text
We don't have the full text on file for this bill yet.
Read HR 7839 on the official United States source →Action History
-
Referred to the Subcommittee on Health.
-
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
-
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
-
Introduced in House
Sponsors
- Doris Matsui · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 546 not signed on
Sponsors (1)
Co-sponsors (0)
None.
Not signed on (546)
546 members have not signed on to this bill.
Show all 546 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does HR 7839 do?
- Extends the Medicare Intravenous Immune Globulin (IVIG) Demonstration for an additional two years and expands the maximum number of participating beneficiaries from 4,000 to 6,500. The program provides bundled payments for items and services that are necessary for in-home IVIG administration for certain beneficiaries with primary immune deficiency disease.
- Who sponsors HR 7839?
- HR 7839 is sponsored by Doris Matsui (D).
- What is the current status of HR 7839?
- This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track HR 7839?
- Track HR 7839 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HR 7839
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HR 7839
Last checked for changes about 17 hours ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →